Because AKT is a signaling mediator downstream of KIT, its activation is downregulated through KIT inhibition – thereby explaining why inhibition of KIT in addition to BCR-ABL1 is needed for a full therapeutic response in CML. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.